NCT00396591 - AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions

Ovarian Neoplasms

Interventions

DRUG

Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)

4.0 mg/kg administered intravenously (IV) once every 2 weeks

Trial Locations (3)

Sanofi-Aventis Administrative Office, Bridgewater

Sanofi-Aventis Administrative Office, Milan

Sanofi-Aventis Administrative Office, Bromma